Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

8.42
+0.29003.57%
Post-market: 8.450.0320+0.38%19:30 EDT
Volume:663.61K
Turnover:5.56M
Market Cap:520.72M
PE:-2.92
High:8.58
Open:8.24
Low:8.19
Close:8.13
52wk High:13.67
52wk Low:3.50
Shares:61.84M
Float Shares:39.72M
Volume Ratio:0.77
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8809
EPS(LYR):-3.6445
ROE:-87.24%
ROA:-44.51%
PB:3.15
PE(LYR):-2.31

Loading ...

Kyverna Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 15

Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright

TIPRANKS
·
May 15

Kyverna Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
May 14

Kyverna Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
May 13

Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
May 13

Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan

TIPRANKS
·
May 13

Wells Fargo Remains a Buy on Kyverna Therapeutics, Inc. (KYTX)

TIPRANKS
·
May 13

Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)

TIPRANKS
·
May 13

BRIEF-Kyverna Therapeutics Reports First Quarter 2026 Financial Results

Reuters
·
May 13

Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate

Benzinga Earnings
·
May 13

Kyverna Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Kyverna Q1 FY26 net loss narrows to $39.7 million

Reuters
·
May 13

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 13

Kyverna Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
May 08

Kyverna Therapeutics Chief Commercial Officer Nadia Dac files initial beneficial ownership statement

Reuters
·
May 07

Press Release: Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Dow Jones
·
May 04

Kyverna Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 23

Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target

TIPRANKS
·
Apr 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway

Reuters
·
Apr 23

Kyverna Therapeutics Shares Rise 7.3% After Co's Rare Muscle Disorder Cell Therapy Shows Strong Mid-Stage Results

THOMSON REUTERS
·
Apr 22